title: [Preoperative Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma].
abstract: BACKGROUND
  The goal of this retrospective study was to investigate the efficacy and safety of preoperative chemoradiotherapy( NACR)in patients with Stage II or Stage III esophageal squamous cell carcinoma(SCC).
  
  
  METHODS
  Between 2004 and 2014, a total of 86 patients underwent surgical resection in conjunction with NACR for esophageal SCC at our institute. Thirty-one patients(36.0%)had Stage II disease and 55 patients(64.0%)had Stage III disease.
  
  
  RESULTS
  The median age was 64(43-81)years. A total of 78 patients received the full NACR regimen. The most common major Grade 3 hematologic toxic effects of NACR were leukopenia and neutropenia(48 cases), while the most common major Grade 3 non-hematologic toxic effect was anorexia(12 cases). One patient died in the hospital and no patients died within 30 days after surgery. A pathological complete response was achieved in 23 cases. Pathological staging(number of cases)was Stage 0(23), Stage I (8), Stage II (28), Stage III (25), and Stage IV (2). The 5-year overall survival rate(OS)was 51.0%, and was 83.2% in Stage II patients and 29.9% in Stage III patients.
  
  
  CONCLUSIONS
  Preoperative NACR is safe and may improve OS and downstaging rates in patients with esophageal SCC.
authors.affiliation: Dept. of Digestive Surgery, Nihon University School of Medicine.
authors.forename: Takaharu
authors.initials: T
authors.lastname: Kawai
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Kochi
authors.forename: Masashi
authors.initials: M
authors.lastname: Fujii
authors.forename: Keio
authors.initials: K
authors.lastname: Song
authors.forename: Ken
authors.initials: K
authors.lastname: Hagiwara
authors.forename: Hidenori
authors.initials: H
authors.lastname: Tamegai
authors.forename: Megumu
authors.initials: M
authors.lastname: Watanabe
authors.forename: Yoritaka
authors.initials: Y
authors.lastname: Matsuno
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Takayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suda
authors.forename: Tadatoshi
authors.initials: T
authors.lastname: Takayama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D016629:Esophagectomy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil